InsidersTradesSigma
Augmedix, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Augmedix, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Augmedix, Inc. has published 77 reports. The latest transaction was disclosed on 4 October 2024 (Disposition). Among the most active insiders: Shakil Ian. Every trade is free.
77
Insider Decl.
0
Thresholds
€9m
7 ops.
Buy Volume
€40m
27 ops.
Sell Volume
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 4 October 2024
Declarations77 total
162,583 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085379:0
74,230 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085351:0
21,598 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085362:0
41,461 shares@ US$2.3590.5% of flowCommon StockSEC:0001104659-24-106311:0
124,126.75 shares@ US$2.3566.1% of flowCommon StockSEC:0001213900-24-085353:0
135,795 shares@ US$2.3573.2% of flowCommon StockSEC:0001213900-24-085356:0
7,701 shares@ US$2.352.2% of flowCommon StockSEC:0001213900-24-085345:0
5,844 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085370:0
20,295 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085366:0
74,230 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085349:0
5,844 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085346:0
64,748 shares@ US$2.35100.0% of flowCommon StockSEC:0001213900-24-085342:0
16,421,788 shares@ US$2.3559.5% of flowCommon StockSEC:0001104659-24-106315:0
6,250 sharesCommon StockSEC:0001213900-24-070867:0
3,750 sharesCommon StockSEC:0001213900-24-070870:0
6,250 sharesCommon StockSEC:0001213900-24-070865:0
4,687 sharesCommon StockSEC:0001213900-24-070863:0
9,375 sharesCommon StockSEC:0001213900-24-070862:0
4,687 sharesCommon StockSEC:0001213900-24-070868:0
3,750 sharesCommon StockSEC:0001213900-24-070875:0
1,322 shares0Common StockSEC:0001013762-24-002827:0
21,598 sharesCommon StockSEC:0001213900-24-061516:0
21,598 sharesCommon StockSEC:0001213900-24-061519:0
21,598 sharesCommon StockSEC:0001213900-24-061517:0
21,598 sharesCommon StockSEC:0001213900-24-061515:0
25 of 77 declarations
About Augmedix, Inc.
Competitively, Augmedix operated in a highly contested healthcare IT niche, facing pressure from larger EHR vendors, outsourced documentation providers, and newer ambient-scribing AI platforms. Its differentiation was based on a mix of software, service delivery, and workflow integration, particularly for enterprise health systems. A major recent milestone was the July 2024 announcement of a definitive agreement to be acquired by Commure in an all-cash transaction valued at roughly $139 million, followed by closing in October 2024 and the subsequent delisting of Augmedix shares from the NASDAQ. For French-speaking investors, Augmedix is best viewed as a U.S. digital health case study marked by rapid sector consolidation rather than a still-listed standalone equity story.
